CSIMarket


Quoin Pharmaceuticals Ltd   (QNRX)
Other Ticker:  
 


 

Quoin Pharmaceuticals Ltd

QNRX's Financial Statements and Analysis



Quoin Pharmaceuticals Ltd reported in the forth quarter of 2023 net loss per share of $-5.22 compare to earnings per share of $4.99 in the same quarter a year ago a decrease compare to $-1.95 realized in previous quarter.


forth quarter of 2023
Earnings Per Share Revenues
$ -5.22 $  0 Mill
$-10.21     Unch.    



Quoin Pharmaceuticals Ltd 's Revenue rose by -88.23 % in forth quarter of 2023 (Dec 31 2023) year on year, to $0 million and declined by sequentially.


Quoin Pharmaceuticals Ltd is

More on QNRX's Income Statement



Quoin Pharmaceuticals Ltd 's in theforth quarter of 2023 recorded net loss of $-6.760 million, an improvement compare to net loss of $-9.447 million in IV. Quarter a year ago.

Sequentially net loss advanced

More on QNRX's Growth

Quoin Pharmaceuticals Ltd Inventories
In Dec 31 2023 company's net cash and cash equivalents decreased by $-1 million


Quoin Pharmaceuticals Ltd does not pay out common stock dividend.

In trailing twelve-month period Quoin Pharmaceuticals Ltd payed $ -8.73 cash per share, on a free-cash flow basis .

Book value fell by -16.30 % sequentially to $6.29 per share, -12.70% of net loss per share in trailing twelve-month period were subtructed from shareholder value.
Tangible Book value fell to $ 5.64 per share from $ 6.88.

Company repurchased 0.09 million shares or 8.72 % in Dec 31 2023.


More on QNRX's Dividends

 Market Capitalization (Millions) 1
 Shares Outstanding (Millions) 1
 Total Debt (Millions $) -
 Revenue (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -13
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ -




Quoin Pharmaceuticals Ltd does not pay out common stock dividend.

In trailing twelve-month period Quoin Pharmaceuticals Ltd had negative $ -8.73 cash flow per share, on a free-cash flow basis .

Book value fell by -16.30 % sequentially to $6.29 per share, -12.70% of net loss per share in trailing twelve-month period were subtructed from shareholder value.
Tangible Book value fell to $ 5.64 per share from $ 6.88.

Company repurchased 0.09 million shares or 8.72 % in Dec 31 2023.


More on QNRX's Balance Sheets

 Market Capitalization (Millions) 1
 Shares Outstanding (Millions) 1
 Total Debt (Millions $) -
 Revenue (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -13
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ -
   


  News about Quoin Pharmaceuticals Ltd Earnings

Quoin Pharmaceuticals Ltd Faces Stock Price Plunge in Fourth Quarter of 2023

Quoin Pharmaceuticals Ltd has recently experienced a significant decline in its stock price. Over the course of the last month, the stock has declined by -64.67%, bringing the share price down to -75.26% in the past 90 days. Currently, the stock is trading on the NASDAQ at a price that is -62.6% below its 52-week average.
One of the reasons for this decline in stock price can be attributed to the company's fourth quarter earnings report for 2023. During this period, Quoin Pharmaceuticals reported a shortfall per stock at $-5.22 per share, compared to $4.99 per share in the previous year's financial reporting period. This represents an increase in the company's shortfall, from $-1.95 per share in the prec...

Quoin Pharmaceuticals Ltd Faces Intensified Deficit in First Quarter of 2023, with Substantial Losses Reported

Quoin Pharmaceuticals Ltd, a company operating in the Healthcare sector, recently reported its financial first-quarter results for 2023, which showed an increased loss per share of $-0.34. This is opposite to the same quarter the previous year, where the company had reported zero loss per share. In the previous quarter, Quoin Pharmaceuticals Ltd had reported a loss of $-0.01 per share.
During the financial first quarter in 2023, the company experienced a net loss of $-2.603 million, as opposed to zero gain in the same quarter of the preceding year. This has resulted in a cumulative net loss of $-24 million during the 12 months ending in the financial first quarter of 2023, which translates to a negative ...


Date modified: 2024-03-15T06:22:48+00:00





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com